Why is Germany's CureVac vaccine just 48% effective? | Covid-19 Special

Why is Germany's CureVac vaccine just 48% effective? | Covid-19 Special

CureVac’s COVID-19 jab did not turn out what many hoped it would be. That’s despite using the same messenger RNA technology as rivals Moderna and BioNTech-Pfizer. CureVac aimed to produce its vaccine primarily for developing countries – as it can be stored more easily than other products. And despite disappointing trial-results the company is sticking to the plan.

Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1

For more news go to: http://www.dw.com/en/
Follow DW on social media:
►Facebook: https://www.facebook.com/deutschewellenews/
►Twitter: https://twitter.com/dwnews
►Instagram: https://www.instagram.com/dwnews
Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch

#CureVac #Covid19 #coronavirus

Video Why is Germany's CureVac vaccine just 48% effective? | Covid-19 Special



Share for free: https://xanhen.com/.

Published
Categorized as Why

Leave a comment

Your email address will not be published. Required fields are marked *